Pep2tango
The startup develops unimolecular multi-receptor peptide agonists that specifically target GLP-1, GIP, amylin, and calcitonin receptors to enhance weight loss therapies. This approach addresses the limitations of first-generation peptide drugs, providing pharmaceutical companies with more effective treatment options for obesity.
Traction –/10
Potomac, United States · HQ
- Biotechnology
Updated 5 months ago
Funding
Raised to date
$16.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops unimolecular multi-receptor peptide agonists that specifically target GLP-1, GIP, amylin, and calcitonin receptors to enhance weight loss therapies. This approach addresses the limitations of first-generation peptide drugs, providing pharmaceutical companies with more effective treatment options for obesity.